CDKAL1 inhibitors represent a class of chemical compounds that have gained attention in the fields of molecular biology and pharmacology due to their role in modulating specific cellular processes. CDKAL1, or CDK5 regulatory subunit-associated protein 1-like 1, is a protein that is primarily associated with the regulation of cyclin-dependent kinase 5 (CDK5), a crucial enzyme involved in cell cycle regulation, neuronal development, and synaptic function. CDKAL1 is known to interact with CDK5 and influence its activity through post-translational modifications. CDKAL1 inhibitors are designed to interact with the active site or binding domain of the CDKAL1 protein, effectively inhibiting its function and influencing cellular processes dependent on CDK5-mediated signaling.
Structurally, CDKAL1 inhibitors are tailored to selectively target the active site of CDKAL1, ensuring high specificity for this particular regulatory protein. By inhibiting CDKAL1, these compounds may disrupt its role in modulating CDK5 activity, which can have far-reaching effects on cell cycle progression, neuronal development, and synaptic plasticity. The study of CDKAL1 inhibitors is of significant interest to researchers as it provides insights into the regulatory mechanisms governing essential cellular functions, particularly in the context of neuronal processes and cell cycle control. This knowledge contributes to our understanding of basic cell biology and may have implications in various research areas, including neurobiology, neurodevelopmental disorders, and cell cycle regulation. However, further research is required to fully explore the extent of their applications and their impact on cellular physiology in the context of CDK5 signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
May influence AMPK pathway, potentially affecting metabolic processes and indirectly CDKAL1 expression. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
As a PPAR-γ agonist, it might modulate transcription factors and potentially affect CDKAL1 expression. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Similar to Rosiglitazone, could influence gene expression related to glucose metabolism, including CDKAL1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which might have downstream effects on metabolic pathways and potentially CDKAL1 expression. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
A sulfonylurea that stimulates insulin secretion, might indirectly affect CDKAL1 expression in pancreatic β-cells. | ||||||
Phenformin Hydrochloride | 834-28-6 | sc-219590 | 10 g | $119.00 | 4 | |
Like Metformin, impacts AMPK pathway, potentially affecting metabolic processes and CDKAL1 expression. | ||||||
Acarbose | 56180-94-0 | sc-203492 sc-203492A | 1 g 5 g | $226.00 $605.00 | 1 | |
Inhibits alpha-glucosidases, could indirectly influence metabolic signaling pathways and CDKAL1 expression. | ||||||
Sitagliptin | 486460-32-6 | sc-482298 sc-482298A sc-482298B | 25 mg 100 mg 1 g | $213.00 $473.00 $733.00 | 10 | |
As a DPP-4 inhibitor, might influence incretin levels and indirectly affect CDKAL1 expression in β-cells. | ||||||
Vildagliptin | 274901-16-5 | sc-208485 | 10 mg | $176.00 | 4 | |
Similar to Sitagliptin, could modulate incretin-related pathways, potentially affecting CDKAL1 expression. | ||||||
Exendin-4 | 141758-74-9 | sc-474611 sc-474611A | 500 µg 1 mg | $146.00 $198.00 | 1 | |
A GLP-1 receptor agonist, could influence signaling pathways in β-cells, potentially affecting CDKAL1 expression. | ||||||